Drug Database
AD

Adenosine (adenosine, Sanofi / Adenoscan inj / Adenosine, Pfizer)

✓ Approved

Astellas Pharma · Small Molecule · Small Molecule

What is Adenosine?

Adenosine is a small molecule developed by Astellas Pharma. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Namesadenosine, Sanofi, Adenoscan inj, Adenosine, Pfizer
CompanyAstellas Pharma
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

Adenosine is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Cardiac disordersArteriosclerosis coronary artery✓ Approved
Hepatobiliary disordersHepatic ischaemia✓ Approved

Related Research Articles

PubMedMethods (San Diego, Calif.)2026-08-30

Purification-free chemical conversion-coupled RT-PCR for ultralow-input detection and quantification of a6A-labelled RNA.

Jiang Shanshan S, Li Wenping W, Shu Xiao X

Nucleoside analogue-based RNA labelling provides powerful approaches for investigating RNA synthesis, turnover, and post-transcriptional regulation. However, conventional detection workflows often require chemical treatment, reagent removal, and repeated RNA purification, which can cause substantial sample loss and limit their application to ultralow-input samples. Here, we present a chemical conversion-coupled RT-PCR method that eliminates post-conversion RNA purification for the detection and quantification of N6-allyladenosine (a6A)-labelled RNA. Iodine-induced cyclization converts a6A into a cyclized adenosine derivative that generates characteristic cDNA mutation signatures during reverse transcription. By eliminating iodine removal, alkaline stabilization, and post-conversion RNA purification, the workflow enables reverse transcription directly from the chemical reaction mixture and reduces handling steps that may otherwise cause sample loss. Optimization of iodine treatment and reverse transcriptase compatibility identified Induro reverse transcriptase as suitable for quantitative analysis because it combined a high mutation rate with the highest estimated read-through efficiency across cyclized a6A sites. The method detected a6A-labelled RNA from femtogram-level inputs and supported mutation-rate-based quantification across a broad input range. Its applicability was further demonstrated by time-resolved tracking of IVT-generated mRNA carrying different poly(A) tails using ultralow amounts of total RNA. This workflow provides a sensitive platform for the detection and relative quantification of a6A-labelled RNA when sample availability is limited.

PubMedFrontiers in cell and developmental biology2026-08-29

Molecular mechanisms by which tumor cell CD73-mediated adenosine signaling drives M2 polarization of macrophages in non-small cell lung cancer.

Zheng Qi Q, Qin Binbin B, Shen Bin B, Huang Yingjun Y et al.

Immune checkpoint inhibitors have improved outcomes for a subset of patients with non-small cell lung cancer (NSCLC), but the immunosuppressive tumor microenvironment (TME) limits their efficacy. Polarization of tumor-associated macrophages (TAMs) toward an M2 phenotype is a key feature of immune escape in NSCLC. Using the CD73 (NT5E)-mediated adenosine metabolic pathway as an entry point, to elucidate its role and molecular mechanisms in driving immunosuppressive TAM polarization in NSCLC. Using TCGA datasets and clinical tissue samples, we analyzed correlations between CD73 expression, macrophage infiltration, and patient prognosis. NSCLC cell lines were used to establish CD73 knockdown/overexpression and pharmacological inhibition models and to quantify extracellular adenosine generation. Tumor cell-conditioned media and Transwell co-culture systems were constructed to induce THP-1 macrophage polarization. Flow cytometry, qPCR, and ELISA were used to assess M1/M2 markers and cytokine profiles. Rescue experiments were performed by supplementing exogenous adenosine or 5'-N-ethylcarboxamidoadenosine (NECA), and adenosine dependence was validated using an A2A receptor antagonist together with downstream cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA)-cAMP response element-binding protein (CREB) signaling measurements. TCGA-based and clinical-sample analyses suggested that high CD73 expression was associated with poorer prognosis and increased infiltration of M2-like macrophages. In vitro experiments confirmed that CD73 expression in NSCLC cells correlated positively with extracellular adenosine production. Pharmacological inhibition or knockdown of CD73 significantly reduced adenosine levels and weakened tumor-derived induction of macrophage M2 polarization, manifested as downregulation of M2 markers with enhancement of the M1 phenotype. Exogenous adenosine supplementation restored M2 polarization, whereas blockade of the A2A receptor or inhibition of the PKA/CREB pathway reversed this polarization effect and attenuated downstream CD8+ T-cell dysfunction-associated changes. CD73-driven adenosine signaling promotes immunosuppressive M2 polarization of NSCLC-associated macrophages through the adenosine-A2A receptor (A2AR)-cAMP/PKA/CREB signaling axis, providing in vitro mechanistic evidence supporting CD73 targeting to improve the tumor immune microenvironment.

PubMedPest management science2026-08-29

Functional characterization of MoHym1 in governing pathogenicity and conferring resistance to DNA damage drugs in Magnaporthe oryzae.

Wang Shuaishuai S, Xu Kun K, Liu Mengqian M, Guo Min M

The rice blast fungus, Magnaporthe oryzae, poses a serious threat to global rice production. Cell cycle and polarized growth are two essential processes for host infection of M. oryzae; however, the association of them remains largely unknown. MoHym1, a homolog of yeast RAM (regulation of Ace2 and morphogenesis) network component, was identified as a key regulator for fungal development and pathogenicity in M. oryzae. Deletion of MoHYM1 resulted in severe defects in vegetative growth, conidiation, polarized growth, cell wall integrity, surface hydrophobicity, and secretion of virulence-associated enzymes, which are essential prerequisites for effective host infection. Furthermore, disruption of MoHYM1 led to abnormal nuclear division and disrupted cell cycle progression while also increasing resistance to DNA-damaging agents hydroxyurea and bleomycin. Yeast-two-hybrid screening revealed interactions with proteins related to adenosine triphosphate (ATP) synthesis. These results position MoHym1 as a multifunctional coordinator of development, cell cycle, and virulence, thereby providing a new target for the control of rice blast. © 2026 Society of Chemical Industry.

PubMedRespiratory medicine case reports2026-08-29

Successful management of fistulous empyema caused by Mycobacterium avium complex in an advanced-age patient: A case report.

Kuze Yusuke Y, Enomoto Yuri Y, Sekinada Daisuke D, Nakano Yoshio Y et al.

Herein, we report the case of an 87-year-old woman who presented with acute chest pain, fever, and cough. Imaging revealed a right pneumothorax, pleural effusion, and bronchiectasis. Pleural fluid was exudative with elevated adenosine deaminase levels, and Mycobacterium avium complex (MAC) was confirmed. Thoracoscopic plication and empyema cavity curettage were performed. Postoperatively, clarithromycin, rifampicin, ethambutol, and amikacin were initiated, leading to clinical improvement, smear and culture negativity, and discharge. Pleuritis caused by nontuberculous mycobacteria (NTM) is rare, occurring in only 1.4% of patients with NTM pulmonary disease; however, pneumothorax has been reported in 41% of these patients. NTM pleural disease with empyema is associated with a poor prognosis, with a 1-year mortality rate of 14-37%. In our report, early diagnosis enabled timely surgical and pharmacological intervention. This report highlights that even in advanced-age patients with preserved performance status, early multidisciplinary management may achieve favorable outcomes in MAC-associated pneumothorax and pleuritis.

PubMedFrontiers in bioengineering and biotechnology2026-08-29

Gold nanoparticle-based colorimetric detection of ATP via a label-free aptamer.

Dai Wenxiu W, Hao Qingqin Q

Adenosine triphosphate (ATP) is an important detection content in many biological reaction detection. At present, the detection methods of ATP mainly focused on electrophoresis, optical analysis, chromatography, and bioluminescence. However, these methods are not widely applied due to the high cost, complicated operation, time-consuming and low sensitivity. Here we developed a simple, fast and sensitive ATP biosensor with the specific aptamer as the recognition element and the unmodified gold nanoparticle (AuNPs) as the colorimetric probe. In the high salt environment, the aggregation of AuNPs causes the color change from red to blue. However, in the presence of aptamer, the free aptamers protect the AuNPs from aggregation and keeps the color of the solution red. Conversely, in the presence of ATP, aptamers are consumed to form aptamer-ATP complex, the AuNPs lose their protection and aggregate with the visual color change from red to blue. Our results show that ATP with a linear range of 5-320 μM can be detected. In conclusion, nanoparticles-based colorimetric method is feasible for ATP detection and has great potential in clinical screening.

PubMedMolecular therapy. Nucleic acids2026-08-29

ADAR RNA editing for cardiovascular disease: Targeting B4GALT1 to modulate lipid metabolism through reduced galactosyltransferase activity.

De Chiara Francesco F, Coll-de la Rubia Eva E, de Bruijn Petra P, Pletikapić Galja G et al.

Cardiovascular disease remains a leading cause of mortality despite current therapies targeting low-density lipoprotein cholesterol (LDL-C). Beta-1,4-galactosyltransferase 1 (B4GALT1), a central glycosyltransferase enzyme that regulates lipoprotein metabolism and hemostasis, is a promising therapeutic target. To evaluate its therapeutic potential as a protective variant, B4galt1 p.Asn352Ser was introduced into the ribonucleic acid (RNA) of healthy wild-type and APOE∗3-Leiden.CETP transgenic mice, a well-established model for hyperlipidemia with a humanized lipoprotein metabolism, using editing oligonucleotides and the endogenous adenosine deaminases acting on RNA enzymes. The impact on hepatic glycosylation and systemic lipid homeostasis was investigated using multi-omics profiling. Editing of B4galt1 messenger RNA (∼9%-18%) resulted in substantial reductions in total cholesterol (-61%), apolipoprotein B (-72%), LDL-C (-30%), fibrinogen (-55%) (all p < 0.05), and triglycerides (-28%; p > 0.05), without altering B4galt1 expression. Proteomics of plasma and liver identified early suppression of lipogenesis and lipoprotein assembly, followed by sustained suppression of cholesterol biosynthesis and coagulation pathways. Glycomic analysis revealed remodeling of circulating glycoprotein architecture, consistent with altered B4GALT1 activity. Transcript-protein concordance was strongest in lipid pathways, while glycosylation and coagulation showed domain-specific regulatory patterns. These findings support targeting B4GALT1 using RNA editing to reduce cardiometabolic risk.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Adenosine